Rivaroxaban (Xarelto) is PBS listed as an alternative to parenteral anticoagulation with heparin and dose-adjusted warfarin for treatment of DVT and prevention of VTE recurrence.
Pregabalin is a treatment option to relieve pain and improve quality of sleep in postherpetic neuralgia and painful diabetic neuropathy.
Imiquimod is an option for the treatment of small, low-risk sBCC when surgery, curettage or cryotherapy are inappropriate.
Juvicor is a fixed-dose combination medicine containing sitagliptin and simvastatin for treating type 2 diabetes and hypercholesterolaemia.
The low-oestrogen-dose combined oral contraceptive levonorgestrel with ethinyloestradiol (Femme-Tab ED 20/100) was listed on the Pharmaceutical Benefits Scheme on 1 April 2013. It was delisted in May 2013.
From 1 April 2013 the Pharmaceutical Benefits Scheme listing of the anti-resorptive agent strontium ranelate is extended to include treatment of osteoporosis in men.
Durotram has been deleted from the list of drugs subsidised on the Pharmaceutical Benefits Scheme.